Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesContraFect Corp

ContraFect Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2024-03-05T21:00:11.320785Z
Market Cap
0.37M

Momentum Score

…

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.03
Low
9.62
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.03
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-1.61M
Debt / Equity
-0.24
ROE
-608.75%
Net Debt
-6.03M
ROCE
40129.19%
Diluted EPS TTM
-10.83

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -65.15M -20.28M -28.16M -12.79M -37.68M
Net income -65.70M 6.85M -27.99M -12.63M -37.68M
Selling general administrative 12.15M 11.76M 11.63M 9.81M 8.71M
Gross profit - - - -1.70M -0.68M
Reconciled depreciation 0.15M 0.15M 0.17M 0.17M 0.15M
Ebit -64.61M -47.27M -34.41M -28.04M -31.28M
Ebitda -53.36M -74.14M -34.24M -27.87M -31.12M
Depreciation and amortization 11.25M -26.87M 0.17M 0.17M 0.15M
Non operating income net other - 26.87M 5.89M 14.71M -7.23M
Operating income -64.61M -47.27M -34.24M -27.87M -31.12M
Other operating expenses 56.89M 47.27M 34.24M 27.87M 31.12M
Interest expense 0.55M 26.98M 0.00M 0.00M 0.00M
Interest income 0.08M 0.11M 0.19M 0.36M 0.67M
Net interest income 0.08M 0.11M 0.19M 0.36M 0.67M
Income tax expense 0.55M -27.13M -0.17M -0.17M -6.56M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 56.89M 47.27M 34.24M 27.87M 31.12M
Cost of revenue - - - 1.70M 0.68M
Total other income expense net -0.55M 26.98M 6.08M 15.07M -6.56M
Net income from continuing ops -65.15M -20.28M -28.16M -12.79M -37.68M
Net income applicable to common shares -65.15M -20.28M -28.16M -12.79M -37.68M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 20.68M 66.76M 51.12M 35.01M 32.87M
Other current assets 2.64M 4.14M 4.16M 6.58M 0.99M
Total liab 32.53M 17.39M 38.50M 19.46M 27.33M
Total stockholder equity -11.85M 49.38M 12.62M 15.54M 5.54M
Deferred long term liab - 2.53M 29.40M 6.07M 21.46M
Other current liab 6.50M 9.13M 3.61M 6.80M 4.37M
Common stock 0.00M 0.00M 0.00M 0.00M 0.01M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.01M
Retained earnings -325.70M -260.55M -240.27M -212.11M -199.32M
Other liab - 2.60M 32.44M 6.14M 21.53M
Other assets 0.10M 0.61M 0.11M 0.11M 0.36M
Cash 8.91M 16.65M 15.48M 24.18M 8.32M
Total current liabilities 20.84M 12.17M 6.06M 10.06M 5.80M
Net debt -6.03M -14.04M -11.88M -20.29M -8.32M
Short term debt 0.67M 0.66M 0.64M 0.63M -
Short long term debt total 2.88M 2.61M 3.60M 3.90M -
Other stockholder equity 313.88M 310.01M 252.91M 227.66M 204.88M
Property plant equipment 2.87M 3.29M 3.72M 1.10M 1.08M
Total current assets 17.71M 62.86M 47.29M 30.76M 31.44M
Net tangible assets -11.85M 49.38M 12.62M 15.54M 5.54M
Short term investments 4.78M 37.63M 27.01M 0.00M 22.13M
Net receivables 2.60M 0.61M 1.10M 0.11M 0.50M
Accounts payable 13.67M 2.39M 1.81M 2.62M 1.43M
Accumulated other comprehensive income -0.03M -0.08M -0.02M -3.25M -0.03M
Common stock total equity - 0.00M 0.00M 0.00M 0.01M
Retained earnings total equity - -260.55M -240.27M -212.11M -199.32M
Non currrent assets other 0.10M 0.61M 0.11M 0.11M 0.36M
Non current assets total 2.97M 3.90M 3.83M 4.25M 1.43M
Capital lease obligations 2.88M 2.61M 3.60M 3.90M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 32.08M -11.61M -27.40M 21.99M 17.28M
Change to liabilities 0.00M 6.10M -4.01M -0.44M 1.13M
Total cashflows from investing activities - -11.61M -27.40M 21.97M 17.15M
Total cash from financing activities 6.14M 53.91M 51.89M 21.32M 10.43M
Change to operating activities 5.00M -4.34M 1.74M -1.26M 0.90M
Net income -65.15M -20.28M -28.16M -12.79M -37.68M
Change in cash -7.75M 1.17M -8.70M 15.86M 1.33M
Begin period cash flow 16.65M 15.48M 24.18M 8.32M 7.00M
End period cash flow 8.91M 16.65M 15.48M 24.18M 8.32M
Total cash from operating activities -45.97M -41.12M -33.19M -27.43M -26.26M
Issuance of capital stock 7.00M 57.50M 55.50M 23.03M 11.50M
Depreciation 0.15M 0.15M 0.17M 0.17M 0.15M
Other cashflows from investing activities - - - 21.99M 17.28M
Sale purchase of stock 10.96M 53.91M 31.39M 21.32M 10.43M
Other cashflows from financing activities -11.81M -3.59M -35.00M -1.71M -1.07M
Change to netincome - -23.68M -5.10M -13.27M 1.56M
Capital expenditures 0.06M 0.00M 0.00M 0.02M 0.13M
Cash flows other operating - -4.34M 3.91M -1.26M 8.10M
Cash and cash equivalents changes - 1.17M -8.70M 15.86M 1.33M
Change in working capital 13.76M 1.76M -2.27M -1.71M 2.00M
Stock based compensation 3.87M 3.19M 2.58M 1.45M 1.56M
Other non cash items 1.39M -25.95M 2.17M -14.54M 7.72M
Free cash flow -46.04M -41.12M -33.19M -27.45M -26.39M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

ContraFect Corp

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

28 Wells Avenue, Yonkers, NY, United States, 10701

914 207 2300

https://www.contrafect.com

23

Name Title Year Born
Dr. Roger James Pomerantz F.A.C.P., FACP, M.D. Chairman, CEO & Pres 1957
Mr. Michael Messinger CPA, CPA Chief Financial Officer 1975
Ms. Natalie Bogdanos J.D. Gen. Counsel, Corp. Sec. & Data Protection Officer 1969
Mr. Matthew Salamone P.H.R., SPHR VP of HR NA
Dr. Gary Woodnutt Sr. VP of Translational Sciences & Preclinical Devel. 1957

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…